Trude Eid Robsahm

Dr. Trude Eid Robsahm


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
TRTrude Eid Robsahm
Trude Eid Robsahm
STSteinar Tretli
Steinar Tretli
ADArne Dahlback
Arne Dahlback
JMJohan Moan
Johan Moan

20 January 2009 in British Journal of Cancer
Verified
Journal Article
Open access
STS Tretli
S Tretli
EHE Hernes
E Hernes
JBJ P Berg
J P Berg
UHU E Hestvik
U E Hestvik
TRTrude Eid Robsahm
Trude Eid Robsahm
Based on observations that for certain cancers, mortality varies according to sun exposure, vitamin D has been proposed to influence on disease progression. This study aims to investigate whether serum levels of 25(OH)D are associated with prognosis in patients with prostate cancer. In total, 160 patients with a serum sample in the JANUS serum bank were included. For 123 patients a pre-treatment serum sample was taken, whereas 37 of the patients had received hormone therapy prior to the blood collection. The serum level of 25(OH)D was classified as low (< 50 nmol l−1), medium (50–80 nmol l−1) or high (>80 nmol l−1). A Cox proportional hazard regression model was used to assess the association between serum 25(OH)D and cancer mortality. During follow-up, 61 deaths occurred, of whom 52 died of prostate cancer. The median time of follow-up was 44.0 months (range, 1.2–154.6). Serum 25(OH)D at medium or high levels were significantly related to better prognosis (RR 0.33; 95% CI 0.14–0.77, RR 0.16; 95% CI 0.05–0.43) compared with the low level. Analysis restricted to patients receiving hormone therapy gave a stronger association. The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients with prostate cancer.

26 January 2015 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TRTrude Eid Robsahm
Trude Eid Robsahm
PHPer Helsing
Per Helsing
MVMarit B Veierød
Marit B Veierød
The incidence of cutaneous squamous cell carcinoma (SCC) is rapidly increasing in white populations, causing high morbidity and health‐care costs. Few studies, however, have described the trends forSCC, as population‐based data with a long follow‐up are limited. In Norway we have this opportunity and we aimed to describeSCCincidence, mortality and survival rates, according to sex, age, stage, primary anatomical location, and geographical region, for the period 1963–2011, for estimation of future health‐care needs. Data were retrieved from the Cancer Registry of Norway. Age‐adjustedSCCincidence and mortality rates and 5‐year relative survival (in percent) were calculated for 5‐year calendar periods. A joinpoint regression model identified the annual percentage change (APC) in rates over the 50‐year period. The age‐adjusted incidence rate increased ninefold in females and sixfold in males from 1963 to 2011, withAPCs of 5.6% (95% confidence interval,CI4.5, 7.3) and 3.3% (95%CI1.3, 5.3) in females and males, respectively.SCCincidence rose in all age groups, anatomical locations (except ears in females), and geographical regions, though restricted to localized tumors. Most striking increase was seen in the age group 70–79, in face and head locations and among residents in southern Norway.SCCmortality and survival rates remained relatively stable. Our findings underline an increasing need forSCCtreatment in Norway, especially considering the aging population. The findings also call for the creation of particular guidelines for primary prevention ofSCC.

1 May 2018 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
TRTrude Eid Robsahm
Trude Eid Robsahm
PHPer Helsing
Per Helsing
YNYngvar Nilssen
Yngvar Nilssen
LVLinda Vos
Linda Vos
SRSyed Mohammad H Rizvi
Syed Mohammad H Rizvi
MVMarit B Veierød
Marit B Veierød
Purpose: The purpose of this study was to examine why Norway has the highest rate of mortality due to cutaneous melanoma (CM) in Europe. The Norwegian Malignant Melanoma Registry (NMMR) enables the study of clinical and histopathological characteristics of patients who die due to CM. Patients and methods: The NMMR and the Norwegian Cause of Death Registry provided data on the clinical and histopathological factors as well as the date and cause of death, through June 2015 for all first invasive CMs diagnosed in 2008–2012 (n=8087). Cox regression was used to estimate associations between clinical and pathological factors and CM-specific death. Multiple imputation was used to handle missing data. Results: The CMs were equally distributed between men (49.9%) and women (50.1%), and the median follow-up was 4.0 years (range: 0.08–7.5 years). Trunk was the most common anatomic site (48%), superficial spreading melanoma was the dominant melanoma subtype (68.2%), median Breslow thickness was 1.0 mm, ulceration was present in 23% of CMs, and 91.8% of cases were in a local clinical stage at diagnosis. Compared to women, men were diagnosed at a higher age, with thicker and more-often-ulcerated tumor, and more often were in advanced clinical stages. During follow-up, 1015 patients died due to CM, representing 52.8% of all deaths. The nodular subtype made up the dominant proportion of fatal CM cases (55.3% in women, 64.6% in men). Sex, age, anatomic site (trunk), T-stage, ulceration, clinical stage, and having a second primary CM were associated with increased risk of CM-specific death. Conclusion: Our data suggest that the high rate of mortality due to CM observed in Norway is attributable to the more advanced stage of the disease at diagnosis. Most high-risk cases occurred in male patients ≥70 years of age. Efforts to improve awareness and secondary prevention of CM, including warning signs of all melanoma subtypes, are required urgently and should be targeted toward men in particular.

26 May 2016 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TRTrude Eid Robsahm
Trude Eid Robsahm
RFRagnhild S. Falk
Ragnhild S. Falk
THTrond Heir
Trond Heir
LSLeiv Sandvik
Leiv Sandvik
LVLinda Vos
Linda Vos
STSteinar Tretli
Steinar Tretli
Physical activity is inversely associated with risk of some cancers. The relation with cancer‐specific death remains uncertain. Mainly, studies on relationships between physical activity and cancer are based on self‐reported physical activity (SPA). Hereby, we examined whether measured cardiorespiratory fitness (CRF) is associated with cancer risk, mortality, and case fatality. We also describe relationships between SPA and these outcomes, and between CRF and SPA. A cohort of 1997 healthy Norwegian men, aged 40–59 years at inclusion in 1972–75, was followed throughout 2012. At baseline, CRF was objectively measured. SPA (leisure time and occupational) was obtained through a questionnaire. Relationships between CRF or SPA, and the outcomes were estimated using Cox regression, adjusted for age, body mass index (BMI), and smoking. Pearson correlation coefficients evaluated agreements between CRF and SPA. During follow‐up, 758 men were diagnosed with cancer and 433 cancer deaths occurred. Analyses revealed lower cancer risk (Hazard ratio [HR] 0.85, 95% confidence intervals [CI]: 0.68–1.00), mortality (HR 0.68, 95% CI: 0.53–0.88), and case fatality (HR 0.74, 95% CI: 0.57–0.96), in men with high CRF compared to low CRF. Light leisure time SPA was associated with lower cancer risk (HR 0.70, 95% CI: 0.56–0.86) and mortality (HR 0.64 95% CI: 0.49–0.83), whereas strenuous occupational SPA was associated with higher risks (HR 1.42, 95% CI: 1.13–1.78 and HR 1.45, 95% CI: 1.09–1.93). Correlations between CRF and SPA were 0.351 (P < 0.001) and −0.106 (P < 0.001) for leisure time and occupational SPA, respectively. A high midlife CRF may be beneficial for cancer risk, cancer mortality, and case fatality.

20 March 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TRTrude Eid Robsahm
Trude Eid Robsahm
RFRagnhild S. Falk
Ragnhild S. Falk
THTrond Heir
Trond Heir
LSLeiv Sandvik
Leiv Sandvik
LVLinda Vos
Linda Vos
STSteinar Tretli
Steinar Tretli
Based on self‐reported physical activity, there is epidemiologic evidence for a beneficial relation between physical activity and colon cancer in men, but findings for other cancers are inconclusive. Measured cardiorespiratory fitness (CRF) can provide knowledge about the cancer‐preventive value of physical activity. We aimed to assess relationships between CRF and risk of site‐specific cancers. A cohort of 1997 healthy Norwegian men, aged 40–59 years at inclusion in 1972–1975, was followed for cancer throughout 2012 using data from the Cancer Registry of Norway. CRF was measured by a maximal exercise bicycle test at inclusion. Relationships between CRF and site‐specific cancers were estimated using Cox regression, adjusted for age, body mass index, and smoking. During follow‐up, 898 cancer cases were diagnosed in 758 men. When comparing men in CRF tertile 1 with men in tertiles 2 and 3, respectively, we found decreased risk of proximal colon cancer in tertile 2 (HR: 0.30, 95% CI: 0.13–0.73) and decreased risk of cancers of lung (0.39 95% CI: 0.22–0.66), pancreas (0.32 95% CI: 0.10–1.00), and bladder (HR: 0.40 95% CI: 0.21–0.74) in tertile 3. Furthermore, a significant trend for lower risk by increasing CRF tertile was found for cancers of proximal colon, lung, and bladder (P‐value for trend <0.05). For other cancer sites, no significant association was found. Our results indicate that high midlife CRF may have cancer‐preventive value.